NEW YORK (GenomeWeb News) – Transgenomic reported after the close of the market on Tuesday that its second quarter sales dropped 20 percent year over year.

Total sales came in at $7.3 million for the three months ended June 30, down from $9.1 million a year ago. The Omaha, Neb.-based firm attributed the decline to "unusually high test volumes" process in the year-ago period, resulting from a backlog following a LIMS software failure during the first quarter of 2012.

Diagnostic Tools revenues were "slightly higher" compared to a year ago, it added.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.